Document Detail


Comparison of the efficacy and safety of moxifloxacin and trovafloxacin for the treatment of acute, bacterial maxillary sinusitis in adults.
MedLine Citation:
PMID:  12590855     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In this multicentre, multinational, comparative, double-blind clinical trial, out-patients with both symptoms and radiographic evidence of acute sinusitis were randomly assigned to receive either a seven-day, once daily (o.d.) oral regimen of moxifloxacin (400 mg) or a 10-day o.d. oral regimen of trovafloxacin (200 mg). Among 452 patients considered valid for clinical efficacy, moxifloxacin treatment was found to be statistically equivalent to trovafloxacin (96.9 per cent vs 92.1 per cent -95 per cent CI = 0.6 per cent; 8.9 per cent) at the seven to 10 days post-therapy assessment. At follow-up, the success rate in the moxifloxacin group was 94.9 per cent and that for the trovafloxacin group was 97.6 per cent (95 per cent CI = -4.9 per cent; 1.3 per cent). The predominant causative organisms were Streptococcus pneumoniae, Haemophilus influenzae and Staphylococcus aureus followed by Enterobacteriaceae and Moraxella catarrhalis. The bacteriological success rate at the post-therapy evaluation was similar in both treatment groups: 94.4 per cent and 90.1 per cent in the moxifloxacin and trovafloxacin groups respectively (95 per cent CI = -3.0 per cent; 11.9 per cent). Only three of the 103 baseline isolated pathogens still persisted in the moxifloxacin group, whereas there were 10 of the 121 isolates that failed to respond in the trovafloxacin treatment group. At least one drug-related event was reported by 16.9 per cent of the moxifloxacin-treated patients and by 22.3 per cent of those who received trovafloxacin. CNS events such as dizziness and vertigo were reported more than five times more often in patients receiving trovafloxacin than in the moxifloxacin group. Trovafloxacin recipients were also more than twice as likely to discontinue treatment due to adverse events than moxifloxacin-treated patients. Overall, moxifloxacin was at least as effective clinically and bacteriologically as trovafloxacin and better tolerated.
Authors:
J-M Klossek; R Siegert; P Nikolaidis; P Arvis; M-A Leberre;
Related Documents :
22135945 - Seito - stockholm eastman index of treatment outcome.
8036475 - Effect of loracarbef and amoxicillin on the oropharyngeal and intestinal microflora of ...
2589355 - Use of ciprofloxacin in cystic fibrosis patients.
22740365 - Distressed partners and caregivers do not recover easily: adjustment trajectories among...
23669885 - Factors affecting quality of anticoagulation control among patients with atrial fibrill...
16467715 - Treatment of chronic posterior laryngitis with esomeprazole.
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  The Journal of laryngology and otology     Volume:  117     ISSN:  0022-2151     ISO Abbreviation:  J Laryngol Otol     Publication Date:  2003 Jan 
Date Detail:
Created Date:  2003-02-19     Completed Date:  2003-03-24     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8706896     Medline TA:  J Laryngol Otol     Country:  England    
Other Details:
Languages:  eng     Pagination:  43-51     Citation Subset:  AIM; IM    
Affiliation:
ENT and Maxillo-facial Department, Hôpital Jean Bernard, Centre Hospitalo-Universitaire de Poitiers, BP 577, 86021 Poitiers Cedex, France. j.m.klossek@chu-poitiers.fr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Adult
Anti-Infective Agents / adverse effects,  therapeutic use*
Aza Compounds*
Bacterial Infections / drug therapy*,  microbiology
Dose-Response Relationship, Drug
Double-Blind Method
Female
Fluoroquinolones*
Humans
Male
Maxillary Sinusitis / drug therapy*,  microbiology
Microbial Sensitivity Tests
Middle Aged
Naphthyridines / adverse effects,  therapeutic use*
Prospective Studies
Quinolines*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Anti-Infective Agents; 0/Aza Compounds; 0/Fluoroquinolones; 0/Naphthyridines; 0/Quinolines; 0/moxifloxacin; 146836-84-2/trovafloxacin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Otomycosis in Turkey: predisposing factors, aetiology and therapy.
Next Document:  Nasal septal perforation repair using open septoplasty and unilateral bipedicled flaps.